RedHill Biopharma Ltd.
opaganib
neuroblastoma
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on opaganib for neuroblastoma is expected Date TBD.
Primary source
· SEC 6-K
verified 13h ago
“The neuroblastoma market is expected to be valued at approximately $3.5 billion in 2032”